Cytokinetics stock gains 3.53 percent to EUR 56.94 versus Tradegate close

Published on 10/20/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 28.62 million. Cytokinetics stock costs EUR 56.94 on October 20, 2026, up 3.53 percent versus Tradegate close.

Price and operating facts

Cytokinetics stock gained 3.53 percent to EUR 56.94 on October 20, 2026.
Second-quarter 2026 revenue was USD 28.62 million and the GAAP net loss was USD 198.76 million.
Cytokinetics stock costs EUR 56.94 at Lang & Schwarz on October 20, 2026 at 7:46 p.m. CEST, 3.53 percent above the Tradegate close of October 19, 2026.
The FDA action date for the MAPLE-HCM application is November 14, 2026.

CYTK, US23282W6057, Illustration mit AI erstellt.

Cytokinetics stock gained 3.53 percent to EUR 56.94 on October 20, 2026, measured against the Tradegate close of October 19, 2026 at EUR 55.00. In the second quarter of 2026, revenue was USD 28.62 million and the GAAP net loss was USD 198.76 million, according to Benzinga. The stock was trading at EUR 56.94 at Lang & Schwarz on October 20, 2026 at 7:46 p.m. CEST, 3.53 percent above that Tradegate close.

Revenue and loss set the backdrop

The second-quarter revenue figure fell from USD 66.77 million in the same period of 2025, while the GAAP net loss widened from USD 134.37 million. Myqorzo contributed USD 25.30 million in net product revenue during the second quarter of 2026, according to Benzinga.

Stock remains below yearly high

The Nasdaq-listed biotechnology company had a USD 54.30 to USD 88.31 52-week range on October 20, 2026. Its current USD 8.9 billion market capitalization and 447,834-share volume provide scale for the move, while the latest USD 64.01 Nasdaq quote was 2.18 percent above the prior session at 1:50 p.m. ET.

What dates matter next?

Cytokinetics has a November 14, 2026 target action date for the MAPLE-HCM application, a regulatory milestone cited by Zacks. The company also expects to submit a supplemental application for aficamten in non-obstructive hypertrophic cardiomyopathy during the fourth quarter of 2026, according to Benzinga.

How does valuation compare?

Cytokinetics reported a negative trailing price-to-earnings ratio of 8.86 on October 20, 2026, reflecting its net loss rather than an earnings-based valuation. Bristol-Myers Squibb traded at USD 61.55 with a price-to-earnings ratio of 13.56 and a USD 125.7 billion market capitalization, while Vertex Pharmaceuticals traded at USD 509.57 with a ratio of 29.66 and a USD 129.2 billion market capitalization. These figures provide broad biotechnology context, but Cytokinetics remains driven by product launch and regulatory milestones.

Price and regulatory milestones

The October 20, 2026 move places the euro quote above the Tradegate close while the stock remains below its 52-week high of USD 88.31. The next material date is the November 14, 2026 MAPLE-HCM action date, with the fourth-quarter aficamten filing plan providing a second calendar marker.

Cytokinetics stock was trading at EUR 56.94 at Lang & Schwarz on October 20, 2026 at 7:46 p.m. CEST, 3.53 percent above the Tradegate close of October 19, 2026 at EUR 55.00. The further course of trading is shown by the continuously updated real-time quote of Cytokinetics stock.